Enpath suffers FDA setback for steroid-eluting heart pacing lead
This article was originally published in Clinica
Executive Summary
The US FDA has told Enpath Medical that it is unable to approve the company's steroid-eluting epicardial pacing lead based on the data and labelling in the firm's marketing application, submitted in July last year.